Condition: Coronary Heart Disease · Percutaneous Coronary Intervention · Colchicine · Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colchicine (0.5 mg/day) was recommended by the U.S. Food and Drug Administration in 2023 for the anti-inflammatory treatment of coronary heart disease (CHD). However, colchicine is still not approved for CHD treatment in China. There is no large-scale clinical evidence that colchicine can be used to treat Chinese patients with CHD. Considering the low body weight of the East Asian population, it is unclear whether the recommended standard dose (0.5 mg/day) is suitable for Chinese patients. Therefore, we need to further explore the effects of different doses of colchicine on the efficacy and safety of clinical endpoints in the Chinese population with CHD. This study is a multicenter, prospective, randomized, controlled, double-blind, event-driven clinical study conducted in China. The primary objective of this study is to determine whether long-term treatment with different doses of colchicine reduces the incidence of cardiovascular events in Chinese patients undergoing PCI. The secondary objective is to determine the safety of long-term treatment with different doses of colchicine in this patient population.
This description comes directly from the study's public registry record.
Miao Yu, MD · +8602785726494 · yumiaodavid@126.com
Always discuss trial participation with your own doctor first.
| The Second Hospital & Clinical Medical School, Lanzhou University | Lanzhou, Gansu, China | Recruiting |
| Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing, China | Recruiting |
| The Second Affiliated Hospital of Chongqing Medical University | Chongqing, China | Recruiting |
| The First Affiliated Hospital of Dalian Medical University | Dalian, China | Recruiting |
| The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture | Enshi, China | Recruiting |
| The First Affiliated Hospital of Harbin Medical University | Harbin, China | Recruiting |
| The First Affiliated Hospital of Anhui Medical University | Hefei, China | Recruiting |
| Huangshi Central Hospital | Huangshi, China | Recruiting |
| Shandong Provincial Hospital | Jinan, China | Recruiting |
| Jingzhou Central Hospital | Jingzhou, China | Recruiting |
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, China | Recruiting |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06472908